Pro-Pointer, Inc., Through Its Wholly Owned Subsidiary Coenzyme-A Technologies, Inc., Announces New Supplement for Cardiovascula
2009年9月21日 - 10:15PM
Marketwired
Pro Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned
subsidiary Coenzyme-A Technologies, Inc., today announced that
their product Coenzyme-A, according to famous nutritional authors
Phyllis A. Balch, CNC and James F. Balch, MD in the FOURTH EDITION
of the best selling nutritional guide to natural health
"Prescription for NUTRITIONAL HEALING," reduces free radical damage
to LDL cholesterol and decreases human platelet aggregation by
supporting the immune system's detoxification of many dangerous
substances. It provides an all-natural way to maintain the healthy,
normal functioning of the heart and the whole cardiovascular
system.
Heart disease is the leading cause of death in the United
States. Clogged arteries (atherosclerosis) can set the stage for
life threatening heart attacks. Published research shows that a
deficiency of metabolic enzymes exists globally, specifically the
"Master Coenzyme, Coenzyme-A." Coenzyme-A Technologies, Inc. has
applied new technology to the formulation of the world's first and
only development of Coenzyme-A and Acetyl Coenzyme-A nutraceutical
supplements.
ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies,
Inc. is an innovative company that has applied new technology to
the formulation and manufacture of a series of proprietary products
which address nutritional deficiencies that result from the stress
of modern day living, chemical imbalances within the body, and the
effects of aging. Coenzyme-A is the first nutraceutical product to
combine nutritional components that can be successfully used by the
body to support its manufacture and utilization of cellular
Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific
set of substrates that are designed to assist the body in
converting fats, carbohydrates and proteins into energy at the
cellular level. See Company website -- www.coenzyme-a.com.
FORWARD LOOKING STATEMENTS
The information contained in this news release, other than
historical information, consists of forward-looking statements
within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act. These statements may involve risks and
uncertainties that could cause actual results to differ materially
from those described in such statements. Such forward-looking
statements involve known and unknown risks and uncertainties,
including all business uncertainties relating to product
development, marketing, market acceptance, future capital
requirements, competition in general and other factors that may
cause actual results to be materially different from those
described herein as anticipated, believed, estimated or expected.
The Company is under no obligation to (and expressly disclaims any
such obligation to) update or alter its forward-looking statements
whether as a result of new information, future events or
otherwise.
Add to Digg Bookmark with del.icio.us Add to Newsvine
INVESTOR RELATIONS at: InvestSource, Inc. 6352 Santa Ynez Dr.
Huntington Beach, CA 92647 Phone (714) 847-2460 Fax (714)
847-4987
Coenzyme A (CE) (USOTC:PPII)
過去 株価チャート
から 2 2025 まで 3 2025
Coenzyme A (CE) (USOTC:PPII)
過去 株価チャート
から 3 2024 まで 3 2025
Real-Time news about Coenzyme A Inc (CE) (その他OTC): 0 recent articles
その他のPro-Pointer, Inc.ニュース記事